CN101160134B - 用于减轻哺乳动物炎症的乳酸菌的选择和应用 - Google Patents

用于减轻哺乳动物炎症的乳酸菌的选择和应用 Download PDF

Info

Publication number
CN101160134B
CN101160134B CN2006800120990A CN200680012099A CN101160134B CN 101160134 B CN101160134 B CN 101160134B CN 2006800120990 A CN2006800120990 A CN 2006800120990A CN 200680012099 A CN200680012099 A CN 200680012099A CN 101160134 B CN101160134 B CN 101160134B
Authority
CN
China
Prior art keywords
cells
lactic acid
acid bacteria
strains
reuteri
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN2006800120990A
Other languages
English (en)
Chinese (zh)
Other versions
CN101160134A (zh
Inventor
埃蒙·康诺利
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Baiogaya Co ltd
Original Assignee
Biogaia AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biogaia AB filed Critical Biogaia AB
Publication of CN101160134A publication Critical patent/CN101160134A/zh
Application granted granted Critical
Publication of CN101160134B publication Critical patent/CN101160134B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/164—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • C12N1/205—Bacterial isolates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K2035/11—Medicinal preparations comprising living procariotic cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
    • C12R2001/00—Microorganisms ; Processes using microorganisms
    • C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
    • C12R2001/225—Lactobacillus
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/8215—Microorganisms
    • Y10S435/822—Microorganisms using bacteria or actinomycetales
    • Y10S435/853—Lactobacillus

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Mycology (AREA)
  • Transplantation (AREA)
  • Molecular Biology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
CN2006800120990A 2005-04-15 2006-04-12 用于减轻哺乳动物炎症的乳酸菌的选择和应用 Active CN101160134B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US11/107,438 2005-04-15
US11/107,438 US7344867B2 (en) 2005-04-15 2005-04-15 Selection and use of lactic acid bacteria for reducing inflammation in mammals
PCT/SE2006/000434 WO2006110088A1 (en) 2005-04-15 2006-04-12 Selection and use of lactic acid bacteria for reducing inflammation in mammals

Publications (2)

Publication Number Publication Date
CN101160134A CN101160134A (zh) 2008-04-09
CN101160134B true CN101160134B (zh) 2012-08-22

Family

ID=37087291

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2006800120990A Active CN101160134B (zh) 2005-04-15 2006-04-12 用于减轻哺乳动物炎症的乳酸菌的选择和应用

Country Status (16)

Country Link
US (2) US7344867B2 (enExample)
EP (1) EP1868622B1 (enExample)
JP (1) JP4740999B2 (enExample)
KR (1) KR101042123B1 (enExample)
CN (1) CN101160134B (enExample)
AU (1) AU2006234793B2 (enExample)
DK (1) DK1868622T3 (enExample)
ES (1) ES2606765T3 (enExample)
HU (1) HUE032297T2 (enExample)
LT (1) LT1868622T (enExample)
MX (1) MX2007012656A (enExample)
PL (1) PL1868622T3 (enExample)
PT (1) PT1868622T (enExample)
RU (1) RU2378370C2 (enExample)
SI (1) SI1868622T1 (enExample)
WO (1) WO2006110088A1 (enExample)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080254011A1 (en) * 2007-04-11 2008-10-16 Peter Rothschild Use of selected lactic acid bacteria for reducing atherosclerosis
US20110293710A1 (en) 2010-02-02 2011-12-01 Delphine Saulnier Immunomodulatory properties of lactobacillus strains
US8785183B2 (en) * 2010-09-21 2014-07-22 Biogaia Ab Active plastic material in oil
US20130022586A1 (en) * 2011-07-21 2013-01-24 James Versalovic Production and use of bacterial histamine
ES2402014B1 (es) 2011-09-07 2014-02-27 Consejo Superior De Investigaciones Científicas (Csic) Peptido secretado por lactobacillus plantarum con función inmunomoduladora
CA3008794C (en) 2012-03-29 2021-03-16 Therabiome, Llc Gastrointestinal site-specific oral vaccination formulations active on the ileum and appendix
CN104755091B (zh) 2012-06-04 2020-07-21 生命大地女神有限公司 预防哺乳动物骨质疏松的乳酸杆菌的选择和应用
RU2015140610A (ru) 2013-03-14 2017-04-17 ТЕРАБАЙОМ, ЭлЭлСи Направленная доставка в желудочно-кишечный тракт пробиотических микроорганизмов и/или терапевтических средств
AU2015209763B2 (en) 2014-01-23 2020-12-24 Biogaia Ab Selection of agents modulating gastrointestinal pain
SG11201705479UA (en) * 2015-03-26 2017-10-30 Biogaia Ab Histamine-producing bacterial strains and their use in cancer
US10376563B1 (en) 2016-02-12 2019-08-13 Wisconsin Alumni Research Foundation Methods for systemically delivering polypeptides and microorganisms therefor
FI3442547T3 (fi) 2016-04-15 2023-09-05 Baylor College Medicine Lactobacillus reuteri MM4-1A käytettäväksi autismikirjon häiriöiden hoidossa tai ehkäisyssä
KR102250597B1 (ko) 2017-11-20 2021-05-11 경희대학교 산학협력단 신규 유산균 및 이의 용도
CN110893195B (zh) * 2019-09-30 2023-03-14 内蒙古伊利实业集团股份有限公司 一种具有缓解肠道炎症功能的副干酪乳杆菌et-22
HUE063707T2 (hu) 2019-11-08 2024-01-28 Biogaia Ab Szerotonintermelõ baktériumok
CN114196581B (zh) * 2020-12-16 2023-06-13 江南大学 缓解高尿酸血症的罗伊氏乳杆菌ccfm1132及应用
AU2022318574B2 (en) 2021-07-30 2024-03-21 Helaina, Inc. Methods and compositions for protein synthesis and secretion
CA3228922A1 (en) 2021-10-11 2023-04-20 Ajinomoto Co., Inc. Bacterium modified to express heterologous tat protein
KR102752058B1 (ko) * 2023-08-25 2025-01-13 전남대학교 산학협력단 락토바실러스 루터리 nchbl-005 균주, 사균체 또는 이의 혼합물을 유효 성분으로 포함하는 염증성 질환 예방, 치료 또는 개선용 조성물

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004031368A1 (en) * 2002-10-07 2004-04-15 Biogaia Ab Selection and use of lactic acid bacteria for reducing inflammation caused by helicobacter

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5413960A (en) 1987-05-01 1995-05-09 Biogaia Ab Antibiotic reuterin
US5458875A (en) 1990-06-15 1995-10-17 Biogaia Ab In ovo method for delivering Lactobacillus reuteri to the gastrointestinal tract of poultry
US5534253A (en) * 1995-06-07 1996-07-09 Biogaia Ab Method of treating enteropathogenic bacterial infections in poultry
US5837238A (en) 1996-06-05 1998-11-17 Biogaia Biologics Ab Treatment of diarrhea
US20010049115A1 (en) * 2000-01-17 2001-12-06 Collins John Kevin Vitro model for gastrointestinal inflammation
AU5773600A (en) * 1999-06-30 2001-01-31 Board Of Regents Of The University Of Nebraska, The Method of isolation of regulated virulence determinants from bacterial pathogens
US6953574B2 (en) * 2002-06-21 2005-10-11 Technology Commercialization, Inc. Method for producing a fermented hydrolyzed medium containing microorganisms
US20040208863A1 (en) 2003-01-30 2004-10-21 James Versalovic Anti-inflammatory activity from lactic acid bacteria

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004031368A1 (en) * 2002-10-07 2004-04-15 Biogaia Ab Selection and use of lactic acid bacteria for reducing inflammation caused by helicobacter

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
S Ménard et al..Lactic acid bacteria secrete metabolites retaining anti-inflammatory properties after intestinal transport.Gut.2004,53821-828. *

Also Published As

Publication number Publication date
RU2007142174A (ru) 2009-05-20
CN101160134A (zh) 2008-04-09
LT1868622T (lt) 2017-01-10
US20080107635A1 (en) 2008-05-08
ES2606765T3 (es) 2017-03-27
EP1868622A1 (en) 2007-12-26
AU2006234793B2 (en) 2010-10-28
JP4740999B2 (ja) 2011-08-03
MX2007012656A (es) 2007-12-13
AU2006234793A1 (en) 2006-10-19
KR101042123B1 (ko) 2011-06-16
PL1868622T3 (pl) 2017-04-28
RU2378370C2 (ru) 2010-01-10
EP1868622B1 (en) 2016-09-28
HUE032297T2 (en) 2017-09-28
KR20070121700A (ko) 2007-12-27
SI1868622T1 (sl) 2017-01-31
DK1868622T3 (en) 2017-01-16
EP1868622A4 (en) 2011-11-02
HK1115730A1 (en) 2008-12-05
PT1868622T (pt) 2016-12-29
US7344867B2 (en) 2008-03-18
US20060233775A1 (en) 2006-10-19
WO2006110088A1 (en) 2006-10-19
JP2008538288A (ja) 2008-10-23

Similar Documents

Publication Publication Date Title
CN101160134B (zh) 用于减轻哺乳动物炎症的乳酸菌的选择和应用
CN101171019B (zh) 免疫功能调节剂
RU2243779C2 (ru) Штамм молочно-кислых бактерий lactobacillus paracasei cncm i - 2116 (ncc 2461), обладающий способностью предотвращать колонизацию кишечника патогенными бактериями, вызывающими диарею, супернатант его культуры и принимаемое внутрь средство для профилактики и/или лечения нарушений, ассоциируемых с диареей
US7678553B2 (en) Selection and use of lactic acid bacteria for reducing inflammation caused by Helicobacter
CA2676956A1 (en) Product containing inactivated probiotic for children or infants
SK71293A3 (en) Biologic pure bacterial culture of lactic fermentation
EP2220210B1 (en) Strains of lactobacillus plantarum as probiotics with immunomodulatory specific effect
MXPA01009017A (es) Cepas de lactobacillus capaces de evitar diarrea causada por bacterias patogenicas y rotavirus.
WO2008079009A1 (en) Immunomodulating probiotic lactic acid bacteria
CN105154362A (zh) 一种可预防胃溃疡的发酵乳杆菌Lactobacillus fermentum suo及其保健用途
HK1115730B (en) Selection and use of lactic acid bacteria for reducing inflammation in mammals
Raju et al. Isolation, Characterization and Sequencing of Lactobacillus from the Oral and Fecal Samples of Healthy Dogs
US20010043933A1 (en) Methods and compositions for modulating the immune systems of animals
KR100887819B1 (ko) 락토바실러스 루테리 균주를 이용하여 포유동물에서 면역 기능을 향상시키는 방법
Adewoyin Immunomodulating Potential of Exopolysaccharide Producing Lactic Acid Bacteria Isolated from Fer-mented Milk Products
McCoy Effects of feeding Lactobacillus reuteri X-18 on blood chemistry and immune parameters in beagle (Canis familiaris) puppies
GERALD The Lactic Microflora of Pigs, Mice and Rats
Pestka Ex vivo effects of Lactobacilli, Streptococci, and Bifidobacteria ingestion on cytokine and nitric oxide production in...

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1115730

Country of ref document: HK

C14 Grant of patent or utility model
GR01 Patent grant
REG Reference to a national code

Ref country code: HK

Ref legal event code: GR

Ref document number: 1115730

Country of ref document: HK

CP03 Change of name, title or address
CP03 Change of name, title or address

Address after: Stockholm, SWE

Patentee after: Baiogaya Co.,Ltd.

Country or region after: Sweden

Address before: Stockholm, SWE

Patentee before: BIOGAIA AB

Country or region before: Sweden